Berkley W R Corp Invests $23.25 Million in Pfizer Inc. $PFE

Berkley W R Corp purchased a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 965,537 shares of the biopharmaceutical company's stock, valued at approximately $23,250,000. Pfizer makes up about 1.1% of Berkley W R Corp's investment portfolio, making the stock its 9th largest holding.

A number of other institutional investors have also modified their holdings of PFE. Brighton Jones LLC grew its position in Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock valued at $17,677,000 after acquiring an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC boosted its stake in shares of Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock valued at $498,000 after purchasing an additional 2,087 shares during the period. United Bank grew its holdings in shares of Pfizer by 12.4% in the second quarter. United Bank now owns 58,087 shares of the biopharmaceutical company's stock valued at $1,408,000 after purchasing an additional 6,415 shares in the last quarter. Sei Investments Co. increased its stake in Pfizer by 31.5% during the 2nd quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company's stock worth $63,889,000 after buying an additional 631,523 shares during the period. Finally, HUB Investment Partners LLC increased its stake in Pfizer by 45.3% during the 2nd quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company's stock worth $2,480,000 after buying an additional 31,896 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have commented on PFE shares. Citigroup boosted their price target on shares of Pfizer from $26.00 to $27.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 29th. UBS Group reiterated a "neutral" rating and issued a $27.00 price objective on shares of Pfizer in a research note on Wednesday, May 27th. Wall Street Zen raised Pfizer from a "hold" rating to a "buy" rating in a research note on Saturday, August 1st. Guggenheim cut their price target on Pfizer from $35.00 to $31.00 and set a "buy" rating on the stock in a report on Friday, August 7th. Finally, Wolfe Research reaffirmed an "underperform" rating and issued a $26.00 price target on shares of Pfizer in a research report on Thursday, May 14th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat, Pfizer has an average rating of "Hold" and an average target price of $28.28.

Pfizer Price Performance

Shares of NYSE PFE opened at $28.33 on Thursday. The stock's 50-day simple moving average is $25.44 and its 200-day simple moving average is $26.29. The firm has a market capitalization of $161.47 billion, a PE ratio of 37.28 and a beta of 0.34. Pfizer Inc. has a fifty-two week low of $23.58 and a fifty-two week high of $28.75. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.68 by $0.09. The firm had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The firm's quarterly revenue was up 2.6% compared to the same quarter last year. During the same period in the prior year, the company posted $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities research analysts forecast that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be issued a $0.43 dividend. The ex-dividend date is Friday, July 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.1%. Pfizer's dividend payout ratio is presently 226.32%.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer has started a European Medicines Agency review for its Lyme disease vaccine. The review is an important regulatory step that could expand Pfizer’s longer-term vaccine portfolio, although it does not guarantee approval or near-term revenue. Pfizer Starts EMA Review For Its Lyme Disease Vaccine
• Positive Sentiment: Recent comparisons with Bristol Myers Squibb suggest Pfizer’s valuation, diversification and oncology portfolio may offer an attractive risk-reward profile. This supports the view that the stock could benefit if new medicines successfully offset declining legacy-product sales. PFE vs BMY: Which Large Oncology Drugmaker Is a Better Stock Now?
• Positive Sentiment: Analysts are focused on Pfizer’s post-second-quarter pipeline and whether upcoming medicines can reset the company’s growth trajectory. The opportunity is meaningful because Pfizer recently exceeded quarterly earnings and revenue expectations, but execution remains key. How Is Pfizer Shaping Its S&P 500 Pipeline After Q2?
• Neutral Sentiment: Pfizer’s dividend remains appealing to income-oriented investors, but comparisons with Abbott Laboratories emphasize that Pfizer offers more turnaround potential while Abbott has a steadier dividend-growth record and broader diversification. Pfizer vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward?
• Neutral Sentiment: Brokerages collectively rate Pfizer “Hold,” indicating that analysts see potential value but lack a strong consensus catalyst for a decisive re-rating. Pfizer Receives Consensus Recommendation of Hold
• Negative Sentiment: Investor caution persists over Pfizer’s need to restore growth before major patent expirations arrive. Articles discussing new medicines frame the pipeline as necessary to counterbalance expected pressure on established products, limiting enthusiasm until launches and approvals produce measurable results. Can New Medicines Reset the Growth Story?

Pfizer Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source